2232
Pharmacoeconomic analysis of linagliptin (Trajenta®) as part of combination therapy in the treatment of type 2 diabetes
Purpose of the study: Determine whether linagliptin is a pharmacoeconomically sound choice when it is included in therapy in patients with insufficient glycemic control, receiving the maximum tolerated dose of metformin in monotherapy, or in combination with sulfonylurea derivatives or thiazolidinediones, as well as in comparison with the IPDP-4 preparations present on the market St. Petersburg.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kulikov A.Yu., Novikov I.V. Pharmacoeconomic analysis of linagliptin (Trajenta®) as part of combination therapy in the treatment of type 2 diabetes // Pharmacoeconomics: Theory and Practice. - 2014. - Vol. 2, No. 3. - P.55-61 DOI: https://doi.org/10.30809/phe.3.2014.4
Comments0